PUMA BIOTECHNOLOGY, INC. (PBYI) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$9.51

From 52W high−0.93%

Volume297308.00

Market cap$495.55M

P/E (TTM)17.9x

P/S (TTM)2.1x

Div yield—

Key dataSep 18, 2026

Open

$9.51

From 52W high

−0.93%

Volume

297308.00

Market cap

$495.55M

ValuationView details →

P/E (Fwd)

30.0x

EV/EBITDA

8.5x

P/E (TTM)

17.9x

RSI (14)

58.4

MomentumView details →

1D Return

+0.84%

YTD Return

+59.08%

SummaryUpdated Jun 1, 2026

Puma Biotechnology, Inc. (NASDAQ:PBYI) is a Los Angeles-based biopharmaceutical company founded in 2010 that focuses on developing and commercializing innovative cancer treatments. The company went public in 2012 and has established itself as a specialized oncology company with a primary focus on HER2-positive breast cancer therapies. Puma's flagship product is NERLYNX (neratinib), an oral medication approved for treating early-stage and advanced HER2-positive breast cancer patients. The company has built a global presence through licensing partnerships and continues to expand its pipeline through clinical development programs and potential in-licensing opportunities.

Ask drillr about PUMA BIOTECHNOLOGY, INC. →

ValuationView details →

P/E (Fwd)

30.0x

P/E (TTM)

17.9x

EV/EBITDA

8.5x

EV/Sales

1.8x

P/S (TTM)

2.1x

P/B (TTM)

3.6x

ProfitabilityView details →

Gross Margin

74.83%

Net Margin

11.55%

EBITDA Margin

20.61%

ROE (TTM)

19.28%

ROA (TTM)

13.86%

Asset Turnover

1.20x

GrowthView details →

Revenue YoY

−2.86%

EPS YoY

−45.29%

FCF YoY

−6.93%

Revenue CAGR 3Y

+0.05%

EPS CAGR 3Y

+212.07%

EBITDA YoY

−24.69%

MomentumView details →

1D Return

+0.84%

YTD Return

+59.08%

1Y Return

+114.14%

RSI (14)

58.4

vs 50D SMA

+8.33%

vs 200D SMA

+30.41%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

2.91x

Quick Ratio

2.64x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.19

EPS Surprise

375.00%

Beats (12Q)

11/12

Next Q EPS Est

$0.09

Avg Surprise (4Q)

153.48%

Rev Surprise

6.60%

Financials snapshotView financials →

Revenue (TTM)

231.24M

Net Income (TTM)

26.72M

Op. CF (TTM)

41.15M

Next earningsNov 5, 2026 →

Latest newsMore news →

Puma Biotechnology initiated ALISCA-Lung2, a Phase II trial of alisertib in combination with paclitaxel for patients with advanced small cell lung cancer.3d ago

Puma Biotech reported Q2 2026 earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.10 per share, and compared to $0.15 per share a year ago.45d ago

Similar companies

XOMA Royalty Corp.XOMA MapLight Therapeutics, Inc.MPLT Eikon Therapeutics, Inc. Common StockEIKN Assembly Biosciences, Inc.ASMB Vogenx Inc.VOGX Contineum Therapeutics, Inc. Class A Common StockCTNM Find similar companies →

Latest newsMore news →

Puma Biotechnology initiated ALISCA-Lung2, a Phase II trial of alisertib in combination with paclitaxel for patients with advanced small cell lung cancer.3d ago Puma Biotech reported Q2 2026 earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.10 per share, and compared to $0.15 per share a year ago.45d ago